Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in...

Paper

Abstract

= 10) until disease progression or vaccine exhaustion. A total of 392 vaccine doses were administered without serious adverse events. Vaccination induced T cell responses to autologous tumor antigen, which were associated with significantly prolonged survival. Vaccination also amplified T cell responses against mutated neoepitopes derived from nonsynonymous somatic tumor mutations, and this included priming of T cells against previously unrecognized neoepitopes, as well as novel T cell clones of markedly higher avidity against previously recognized neoepitopes. We conclude that the use of oxidized whole-tumor lysate DC vaccine is safe and effective in eliciting a broad antitumor immunity, including private neoantigens, and warrants further clinical testing.

Analysis

Paper intelligence

Summary

This study demonstrates that a personalized whole-tumor lysate dendritic cell vaccine is safe and effective in eliciting broad antitumor immunity in ovarian cancer patients, leading to prolonged survival.

Key findings

Vaccination induced T cell responses to autologous tumor antigen.
T cell responses were associated with significantly prolonged survival.
Vaccination amplified T cell responses against mutated neoepitopes.
The vaccine primed T cells against previously unrecognized neoepitopes and novel T cell clones of higher avidity.

Methods

Administration of oxidized whole-tumor lysate dendritic cell vaccine.
Monitoring of T cell responses to autologous tumor antigen and neoepitopes.
Assessment of survival and adverse events.

Limitations

The abstract does not explicitly state limitations of the study.

Applications

Personalized cancer vaccines for ovarian cancer.
Integration with other immunotherapies.

Confidence100%

Discovery

Related papers

2026Crossref0 citations

Evaluation of Computational Neoantigen Prioritization Strategies for Personalized Cancer Vaccines

Vladimir Zyrin; Evgeniy Mozheiko; Ivan Valiev; Alexey Lazarev; Tigran Gevorkyan; Matvey Murashko; Konstantin Okonechnikov

Sep 28, 2026Vaccines

2026Crossref0 citations

First mRNA‑based flu vaccine wins US approval, Moderna’s Ebola candidate reaches the clinic, and early‑phase cancer vaccine trials broaden across personalized and off‑the‑shelf platforms

Ashling Cannon

Sep 10, 2026Vaccine Insights

2026arXiv

Optimizing RNA yield using deep neural networks coupled to massively parallel screening

Dinghai Zheng; Justin Hong; Jun Wang; Adrien Villain; Mickaël Costallat; Fernando Ulloa Montoya; Vikram Agarwal

Aug 24, 2026

2026Crossref0 citations

Artificial intelligence in peptide cancer vaccine design: from neoantigen discovery to immunogenicity prediction

Petar Brlek; Jan Kolić; Luka Bulić; Vedrana Škaro; Dragan Primorac

Jul 29, 2026Frontiers in Genetics

2026Crossref0 citations

Neoantigen-Encoded Oncolytic Viruses as Personalized Cancer Vaccines

Almohanad A. Alkayyal

Feb 26, 2026Pharmaceuticals

2026PubMed

Longer-term response to SARS-CoV-2 vaccination after allogeneic blood stem cell transplantation.

Crodel CC; Gork L; Göpel W; Linke P; Sinn K; Miethke J; Hochhaus A; Hilgendorf I

Jan 1, 2026Journal of cancer research and clinical oncology

Source record

Publication metadata

Authors: János L. Tanyi; Sara Bobisse; Eran Ophir; Sandra Tuyaerts; Annalisa Roberti; Raphaël Genolet; Petra Baumgärtner; Brian J. Stevenson; Christian Iseli; Denarda Dangaj Laniti; Brian J. Czerniecki; Aikaterini Semilietof; Julien Racle; Alexandra Michel; Ioannis Xénarios; Cheryl Chiang; Dimitri Monos; Drew A. Torigian; Harvey Nisenbaum; Olivier Michielin; Carl H. June; Bruce L. Levine; Daniel J. Powell; David Gfeller; Rosemarie Mick; Urania Dafni; Vincent Zoete; Alexandre Harari; George Coukos; Lana E. Kandalaft
Published: Apr 11, 2018
Journal or venue: Science Translational Medicine
DOI: 10.1126/scitranslmed.aao5931
Paper type: journal article
Source: Openalex

DOI OpenAlex